226 related articles for article (PubMed ID: 33737072)
1. Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation.
Rashid K; Ahmad A; Liang L; Liu M; Cui Y; Liu T
Drug Discov Today; 2021 Jul; 26(7):1689-1701. PubMed ID: 33737072
[TBL] [Abstract][Full Text] [Related]
2. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.
Hushmandi K; Einollahi B; Saadat SH; Lee EHC; Farani MR; Okina E; Huh YS; Nabavi N; Salimimoghadam S; Kumar AP
Mol Metab; 2024 Jun; 84():101952. PubMed ID: 38705513
[TBL] [Abstract][Full Text] [Related]
3. Prognostic SLC family genes promote cell proliferation, migration, and invasion in hepatocellular carcinoma.
Fang X; Liu Y; Xiao W; Zhao N; Zhu C; Yu D; Zhao Y
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1065-1075. PubMed ID: 34128989
[TBL] [Abstract][Full Text] [Related]
4. Solute carriers (SLCs) in cancer.
El-Gebali S; Bentz S; Hediger MA; Anderle P
Mol Aspects Med; 2013; 34(2-3):719-34. PubMed ID: 23506905
[TBL] [Abstract][Full Text] [Related]
5. Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review.
Anagnostakis F; Kokkorakis M; Markouli M; Piperi C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298344
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of the solute carrier family in pancreatic cancer.
Wu Z; Xu J; Liang C; Meng Q; Hua J; Wang W; Zhang B; Liu J; Yu X; Shi S
Clin Transl Med; 2021 Mar; 11(3):e356. PubMed ID: 33783998
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional annotation of solute carrier transporters: implication for drug discovery.
Dvorak V; Superti-Furga G
Expert Opin Drug Discov; 2023; 18(10):1099-1115. PubMed ID: 37563933
[TBL] [Abstract][Full Text] [Related]
8.
Lavoro A; Falzone L; Tomasello B; Conti GN; Libra M; Candido S
Front Pharmacol; 2023; 14():1191262. PubMed ID: 37397501
[No Abstract] [Full Text] [Related]
9. Targeting solute carriers to modulate receptor-ligand interactions.
Sijben HJ; Superti-Furga G; IJzerman AP; Heitman LH
Trends Pharmacol Sci; 2022 May; 43(5):358-361. PubMed ID: 35232590
[TBL] [Abstract][Full Text] [Related]
10. Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.
Bharadwaj R; Jaiswal S; Velarde de la Cruz EE; Thakare RP
Diseases; 2024 Mar; 12(3):. PubMed ID: 38534987
[TBL] [Abstract][Full Text] [Related]
11. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.
Nantajit D; Lin D; Li JJ
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1697-713. PubMed ID: 25270087
[TBL] [Abstract][Full Text] [Related]
12. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities.
Schlessinger A; Zatorski N; Hutchinson K; Colas C
Trends Biochem Sci; 2023 Sep; 48(9):801-814. PubMed ID: 37355450
[TBL] [Abstract][Full Text] [Related]
13. The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice.
Xu C; Zhu L; Chan T; Lu X; Shen W; Gillies MC; Zhou F
PLoS One; 2015; 10(3):e0120760. PubMed ID: 25789863
[TBL] [Abstract][Full Text] [Related]
14. Membrane transporter proteins: a challenge for CNS drug development.
Girardin F
Dialogues Clin Neurosci; 2006; 8(3):311-21. PubMed ID: 17117613
[TBL] [Abstract][Full Text] [Related]
15. Role of solute carrier transporters in regulating dendritic cell maturation and function.
Shao L; Yang M; Sun T; Xia H; Du D; Li X; Jie Z
Eur J Immunol; 2024 Feb; 54(2):e2350385. PubMed ID: 38073515
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers.
Cui S; Gao Y; Zhang K; Chen J; Wang R; Chen L
Cell Physiol Biochem; 2015; 36(2):409-22. PubMed ID: 25968091
[TBL] [Abstract][Full Text] [Related]
17. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.
Joyce H; McCann A; Clynes M; Larkin A
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015
[TBL] [Abstract][Full Text] [Related]
18. Solute carrier transporters: emerging central players in tumour immunotherapy.
Chen R; Chen L
Trends Cell Biol; 2022 Mar; 32(3):186-201. PubMed ID: 34511324
[TBL] [Abstract][Full Text] [Related]
19. Solute carriers as drug targets: current use, clinical trials and prospective.
Rask-Andersen M; Masuram S; Fredriksson R; Schiöth HB
Mol Aspects Med; 2013; 34(2-3):702-10. PubMed ID: 23506903
[TBL] [Abstract][Full Text] [Related]
20. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.
Kirtane AR; Kalscheuer SM; Panyam J
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1731-47. PubMed ID: 24036273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
